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Abstract
Background: Increasing the dosage of daptomycin may be advantageous in severe infection by enhancing
bactericidal activity and pharmacodynamics. However, clinical data on using daptomycin at doses above 6 mg/kg
in Asian population are limited.
Methods: A retrospective observational cohort study of all hospitalized adult patients treated with daptomycin
(> 6 mg/kg) for at least 72 hours was performed in Taiwan.
Results: A total of 67 patients (40 males) with a median age of 57 years received a median dose of 7.61 mg/kg
(range, 6.03-11.53 mg/kg) of daptomycin for a median duration of 14 days (range, 3–53 days). Forty-one patients
(61.2%) were in intensive care units (ICU). Sites of infections included complicated skin and soft tissue infections
(n = 16), catheter-related bacteremia (n = 16), endocarditis (n = 11), primary bacteremia (n = 10), osteomyelitis and
septic arthritis (n = 9), and miscellaneous (n = 5). The median Pitt bacteremia score among the 54 (80.6%) patients
with bacteremia was 4. The most common pathogen was methicillin-resistant Staphylococcus aureus (n = 38).
Fifty-nine patients (88.1%) were treated with daptomycin after glycopepetide use. Overall, 52 (77.6%) patients achieved
clinical success. The all-cause mortality rate at 28 day was 35.8%. In multivariate analysis, the significant predictors of
in-hospital mortality in 54 bacteremic patients were malignancies (P = 0.01) and ICU stay (P = 0.02). Adverse effects of
daptomycin were generally well-tolerated, leading to discontinuation in 3 patients. Daptomycin-related creatine
phosphokinase (CPK) elevations were observed in 4 patients, and all received doses > 8 mg/kg.
Conclusions: Treatment with high dose daptomycin as salvage therapy was generally effective and safe in Taiwan.
CPK level elevations were more frequent in patients with dose > 8 mg/kg.
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Background
Daptomycin, a cyclic lipopeptide antibiotic, has a
rapid, concentration-dependent bactericidal activity
against clinically relevant gram-positive organisms,
such as Staphylococcus aureus (including methicillin-
resistant S. aureus, MRSA) and enterococci (including
vancomycin-resistant enterococci, VRE). The approved
dose of daptomycin is 4 mg/kg for the treatment of
complicated skin and skin structure infections and 6 mg/kg
for S. aureus bacteremia, including right-sided infective
endocarditis [1,2]. Creatine phosphokinase (CPK) level ele-
vation with associated muscular symptoms, has been a con-
cern during daptomycin treatment [3].
Among patients suffering from infections in the inten-
sive care units (ICU), S. aureus, predominantly MRSA,
remains one of the most common causative organism (up
to 20%) [4]. S. aureus isolates with reduced daptomycin
susceptibility, especially after receiving prior glycopeptitide
therapy, have been described and were associated with
clinical failure [5-7]. Increased activity with higher doses,
especially against isolates with reduced susceptibility, was
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demonstrated in some in vitro and animal studies [8-10].
The area under the plasma concentration time curve
(AUC) and trough level of daptomycin increased pro-
portionally with escalating doses [11]. Thus, increasing
doses of daptomycin seems attractive for severe infections,
critically ill patients, or prior treatment failure with glyco-
peptides [12]. The experience with high dose daptomycin
(> 6 mg/kg) is still limited worldwide, and it is unclear
whether this strategy improves outcomes [13-17].
Previous data in Taiwan demonstrated similar pharma-
cokinetics profiles of daptomycin between Taiwanese and
Caucasian population, and supported daptomycin as a
promising and safe agent for severe staphylococcal infec-
tions [18,19]. Our objective in this study was to evaluate
the clinical efficacy and safety of high-dose daptomycin
for serious infections among adult patients, especially




This retrospective observational cohort included hospita-
lized patients who were treated with intravenous daptomy-
cin (Cubicin, Cubist Pharmaceuticals, Lexington, MA) at
the National Taiwan University Hospital (NTUH), a ter-
tiary medical center of 2200 beds, from September 2009 to
October 2010. Audit by an infectious diseases physician is
necessary to prescribe daptomycin at NTUH, therefore all
patients receiving daptomycin during the study period
could be identified at onset of therapy. To be eligible,
patients had to be more than 18 years old and received
daptomycin intravenously at doses more than 6 mg per
kilogram of body weight for at least 72 hours. The dosage
and duration of daptomycin were determined by the physi-
cians in charge and consulting infectious diseases specia-
lists (Lai CC, Sheng WH, and Wang JT). Daptomycin
dosing was based on mg per kg of actual body weight. The
intervals were every 24 hours for patients with creatinine
clearance >30 mL/min and every 48 hours for patients with
creatinine clearance below 30 mL/min, respectively. The
maximal dosing of daptomycin was 12 mg/kg/day [11].
The definitions of high-dose daptomycin were diverse.
Both 6 and 8 mg/kg have been used as the cut-off values
in the literature [13,14,16,17]. Based on the preparation
of daptomycin is 500 mg per vial in Taiwan and an aver-
age body weight of 60 kilogram among Taiwanese adults,
we divided our study cohort (all treated with doses more
than 6 mg/kg) into two groups based on daptomycin
doses (> 8 mg/kg or ≤ 8 mg/kg) and evaluated their
safety and efficacy separately.
Ethics statement
This research conformed to the Helsinki Declaration
and local legislation, and was approved by the National
Taiwan University Hospital Research Ethics Committee
(No. NTUH-200908009R). The committee waived the
need for written informed consent for participation in
the study because of the observational nature of the
study design and retrospective data collection. The clin-
ical samples in the study were not collected for research
purposes, but as part of standard care.
Data collection
A standard case record form was used for data collection.
Clinical data were collected from their medical records,
including age, sex, underlying diseases, clinical diagnosis,
microbiologic isolate identification and antibiotic suscepti-
bility, indication for daptomycin use, use of sequential or
concurrent antibiotics, dose and duration of daptomycin,
and adverse events. CPK levels were checked at least once
per week during treatment with daptomycin based on
infectious diseases physicians’ recommendation. Creatin-
ine clearance was calculated at baseline according to the
Cockcroft–Gault formula. The Charlson comorbidity
index was used to evaluate comorbidity conditions of
the patients [20]. The clinical severities were assessed
by the Pitt bacteremia scores [21]. Sequential Organ
Failure Assessment (SOFA) scores were calculated for
ICU patients within 24 hours of initiation of high-dose
daptomycin therapy.
Bacterial culture and drug susceptibility tests
Culture, identification, and susceptibility testing of clinical
isolates were performed according to standard microbio-
logical methods [22]. BACTEC (Becton Dickinson, Spark,
MD, USA) automated bacterial blood culture systems
were used to facilitate rapid identification. Other clinical
specimens were plated onto a sheep blood agar (SBA)
plate. S. aureus isolates were spotted onto ChromAgar
MRSA to check for methicillin resistance [23]. The sus-
ceptibilities of MRSA isolates to vancomycin were deter-
mined as minimum inhibitory concentrations (MICs)
using Etest (AB Biodisk, Solna, Sweden) [24].
Outcomes and safety evaluation
All patients were followed until death or discharge. Out-
comes were evaluated at the time of 14 days and 30 days
after daptomycin start, and at the end of hospitalization.
Clinical success was defined as resolution of the signs and
symptoms of attributed infections during treatment with
daptomycin. Microbiological success was defined as the
eradication or presumed eradication of infecting patho-
gens at sites of infection [13,16]. The following conditions
was also counted as clinical failure: (1) infection-related
death, (2) persistence of the signs or symptoms of infec-
tion after initiating 72 hours of therapy with daptomycin,
(3) relapse or recurrence of infections within 30 days after
discharges, or (4) replacement of daptomycin with other
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anti-gram positive antimicrobial agents. Persistent positive
cultures from blood or infection sites after 72 hours after
receiving daptomycin were counted as microbiological
failure [13]. Infection-related death was defined as (1) per-
sistent isolation of pathogens from the infection sites at
death, (2) death before resolution of symptoms and signs
of infection, or (3) death within 14 days after the onset of
infection without other attributable causes [25].
Elevations of CPK level were defined as (1) CPK values ≥ 3
times the upper limit of normal (ULN) based on two serial
measurements during therapy, and one of two levels ≥ 5
times the ULN or (2) CPK levels ≥ 5 times the ULN on two
serial measurements if abnormal CPK levels at baseline
[26]. The ULN of CPK value at NTUH is 160 IU/L.
Statistical analyses
SPSS software was used to analyze the data (IBM
Corporation. NY, USA). Categorical data were ana-
lyzed using chi-square or Fisher’s exact tests, as ap-
propriate, and continuous variables were compared using
the Wilcoxon test. A P value of < 0.05 was considered sig-
nificant (two-tailed test). A multivariate model was used
to analyze the predictors of in-hospital mortality among
bacteremic patients receiving daptomycin therapy.
Results
During the study period, a total of 67 hospitalized adult
patients had documented gram-positive bacterial infec-
tions and received high-dose daptomycin therapy for
more than 72 hours. The demographic data are shown
in Table 1. Nearly 70% of episodes were attributable to
healthcare-associated infections. Over one fourth of
patients had renal failure and required renal replace-
ment therapy during hospitalization. Hematologic and
solid organ malignancies were present in one third
(34.3%) of patients. During treatment with daptomycin,
41 (61.2%) patients had been hospitalized in ICU, with a
median SOFA score of 7 (interquartile range, 4–12).
Thirty-three of 67 patients (49.3%) required ventilator
support when receiving daptomycin therapy.
The most common causative pathogen was MRSA
(56.7%), followed by VRE (26.9%) and methicillin-
resistant coagulase-negative staphylococci (MRCoNS)
(14.9%) (Table 2). MIC of vancomycin was checked in
31 of stored MRSA isolates, and MIC ≥ 2 μg/mL were
found in 24 (77.4%) of them. The median of MIC of
vancomycin of MRSA isolates was 2 μg/mL with a range
from 1 μg/mL to 3 μg/mL. Complicated skin and soft
tissue infections (23.9%) and indwelling catheter-related
bacteremia (23.9%) were the most common infections.
Among 11 patients with endocarditis, 10 were left-sided
and one was right-sided. Fifty-four patients (80.6%) were
bacteremic, and the median Pitt bacteremia score was 4
(range, 0–10) (Table 1).
Our cohort was heavily-treated before, and daptomycin
was used as salvage therapy in 63 patients (94%). Among
these patients, the reasons of replacement to daptomycin
included clinical or microbiological failure on prior anti-
microbial therapy (n = 36), isolates with documented high
MIC of glycopeptides (n = 18), and intolerance with grade
3 to 4 toxicities to prior antibiotic therapy (n = 9). Overall,
prior use of glycopeptides was found in 59 patients (88.1%).
None received gentamicin or rifampin concurrently during
daptomycin therapy. There were no differences in baseline
underlying diseases, types of infections, disease severity,
and causative pathogens between these two groups, except
that patients with endocarditis were significantly more
likely to receive daptomycin > 8 mg/kg (P = 0.03) (Table 2).
The all-cause mortality rate at 14 and 28 day was
16.4% and 35.8%, respectively. The overall in-hospital
Table 1 Clinical characteristics of 67 patients with
high-dose daptomycin therapy
Characteristica Daptomycin dose (mg/kg)
≤ 8 (n = 41) > 8 (n = 26) P value
Age, years 56 (18–89) 58.5 (22–87) 0.57
Male (%) 23 (56.1%) 17 (65.4%) 0.45
Weight, kg 56 (37–89) 61.5 (42–87) 0.13
Creatinine clearance,
mL/min
38 (5–263) 57.5 (10–210) 0.54
Indwelling catheter useb 31 (75.6%) 16 (61.5%) 0.22
Surgery within 3 months 13 (31.7%) 10 (38.5%) 0.57
Underlying diseases
Diabetes mellitus 14 (34.1%) 8 (30.8%) 0.77
Cirrhosis of liver 1 (2.4%) 4 (15.4%) 0.14
ESRD 11 (26.8%) 7 (26.9%) 0.99
Heart failure 11 (26.8%) 11 (42.3%) 0.19
Chronic lung disease 5 (12.2%) 3 (11.5%) 0.94
Malignancy 17 (41.5%) 6 (23.1%) 0.12
Charlson index 4 (0–11) 3.5 (0–11) 0.46
Pitt bacteremia scorec 4 (0–10) 3 (0–7) 0.85
ICU stay 24 (58.5%) 17 (65.4%) 0.58
SOFA scored 7 (2–17) 8 (0–17) 0.49
Ventilator use 19 (46.3%) 14 (53.8%) 0.55
Previous anti-gram
positive antibiotic
Vancomycin 28 (68.3%) 22 (84.6%) 0.14
Teicoplanin 13 (31.7%) 9 (34.6%) 0.81
Linezolid 5 (12.2%) 4 (15.4%) 0.71
a Data are median (range) for continuous variables.
b Including central venous catheter, port-A catheter, Hickman catheter,
temporal pacemaker, and intra-aortic balloon pump.
c Only for bacteremic patients.
d Only for ICU patients.
ESRD, end-stage renal disease; ICU, intensive care unit; SOFA, Sequential Organ
Failure Assessment; VHD, valvular heart disease.
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mortality was 49.3% (33 out of 67 patients) and infection-
related mortality (proportionate mortality) was 27.3%
(9 out of 33 patients). The other causes of death included
healthcare-associated infections due to gram-negative bac-
teria (n = 10, among which eight were pneumonia and two
bacteremia cases) and invasive candidiasis (n = 3), advanced
malignancies (n = 6), cardiac events (n = 3), hepatic failure
(n = 1), and stroke (n = 1). ICU patients had significantly
higher 28-day and in-hospital mortality rates compared to
non-ICU patients (46.3% versus 19.2% and 68.3% versus
19.2%, respectively; p < 0.05 for both). Overall, 55 (82.1%)
patients achieved microbiological success and 52 (77.6%)
patients had clinical success. The ICU patients had similar
rates of microbiological success (87.8%) and clinical
success (80.5%). These outcomes were comparable in the
two dosage groups (≤ 8 mg/kg group versus > 8 mg/kg
group), even in ICU patients or excluding patients with
endocarditis (Table 3). Patients treated with daptomycin
due to prior treatment failure had lower rate of clinical suc-
cess, compared to those treated with daptomycin due to
prior adverse drug events (63.9% versus 96.3%, P < 0.01).
Only one patient with endocarditis had recurrent infection
within 30 days after discharge. In multivariate analysis,
the significant predictors of in-hospital mortality in 54
patients with bacteremia received daptomycin were under-
Table 2 Types of infections, pathogens and dosage of
67 patients with high-dose daptomycin therapy
Characteristica Total (n = 67) Daptomycin dose (mg/kg)
≤ 8 (n = 41) > 8 (n = 26) P
value
Pathogen
MSSA 6 (9.0%) 4 (9.8%) 2 (7.7%) 0.77
MRSA 38 (56.7%) 23 (56.1%) 15 (57.7%) 0.90
Vancomycin MIC
≥ 2 μg/mL
24 (35.8%) 14 (34.1%) 10 (38.5%) 0.80
MRCoNS 10 (14.9%) 6 (14.6%) 4 (15.4%) 0.93





18 (26.9%) 10 (24.4%) 8 (30.8%) 0.57
All bacteremia 54 (80.6%) 32 (78.0%) 22 (84.6%) 0.75
Primary
bacteremia
10 (14.9%) 7 (17.1%) 3 (11.5%) 0.54
Endocarditis 11 (16.4%) 3 (7.3%) 8 (30.8%) 0.03
Catheter-related
bacteremia
16 (23.9%) 11 (26.8%) 5 (19.2%) 0.48
cSSTI 16 (23.9%) 9 (22%) 7 (26.9%) 0.64
Bone & joint
infection
9 (13.4%) 6 (14.6%) 3 (11.5%) 0.72
Otherb 5 (7.46%) 5 (12.2%) 0 (0%) 0.15
Duration of
therapy, days




a Data are median (range) for continuous variables.
b Including urinary tract infections (n = 3) and intra-abdominal infections (n = 2).
cSSTI, complicated skin and soft-tissue infection; MIC, minimum inhibitory
concentration; MRCoNS, methicillin-resistant coagulase-negative staphylococci;
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus;
VRE, vancomycin-resistant enterococci.
Table 3 Outcomes and adverse events of patients with
high-dose daptomycin therapy
Characteristic Total (n = 67) Daptomycin dose (mg/kg)
≤ 8 (n = 41) > 8 (n = 26) P
value
14-day mortality 11 (16.4%) 6 (14.6%) 5 (19.2%) 0.74
28-day mortality 24 (35.8%) 13 (31.7%) 11 (42.3%) 0.44
In-hospital
mortality
33 (49.3%) 20 (48.8%) 13 (50.0%) 0.92
ICU patients
(n = 41)





9 (13.4%) 5 (12.2%) 4 (15.4%) 0.73
ICU patients
(n = 41)
7 (17.1%) 4/24 (16.7%) 3/17 (17.6%) >0.99
Clinical success 52 (77.6%) 32 (78.0%) 20 (76.9%) 0.91
All bacteremia
(n = 54)
43 (79.6%) 27/32 (84.4%) 16/22
(72.7%)
0.32




MIC ≥ 2 μg/mL
(n = 24)
19 (79.2%) 13/14 (92.9%) 6/10 (60%) 0.12
VRE (n = 18) 12 (66.7%) 7/12 (58.3%) 5/6 (83.3%) 0.60
Endocarditis
(n = 11)




15 (93.8%) 10/11 (90.9%) 5/5 (100%) 0.59
cSSTI (n = 16) 14 (87.5%) 7/9 (77.8%) 7/7 (100%) 0.48
Bone & joint
infection (n = 9)
6 (66.7%) 4/6 (66.7%) 2/3 (66.7%) >0.99
Microbiological
success
55 (82.1%) 36 (87.8%) 19 (73.1%) 0.19
Adverse events
Cytopenia 47 (70.2%) 28 (68.3%) 19 (73.1%) 0.68
Renal
dysfunction
14 (20.9%) 8 (19.5%) 6 (23.1%) 0.73
Elevated AST/ALT 20/66 (30.3%) 12/41 (29.3%) 8/25 (32.0%) 0.82
CPK elevations
Any 16 (29.2%) 7/37 (18.9%) 9/24 (37.5%) 0.11
By definition 4/61 (6.6%) 0/37 (0%) 4/24 (16.7%) 0.02
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine
phosphokinase; cSSTI, complicated skin and soft-tissue infection; MIC,
minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; VRE,
vancomycin-resistant enterococci.
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lying malignancies (adjusted odds ratio [AOR], 21.67; 95%
confidence interval [95% CI], 1.94-242.32, P = 0.01) and
ever ICU stay (AOR, 45.36; 95% CI, 2.07-995.25, P = 0.02).
During daptomycin therapy, the most common ad-
verse events observed were bone marrow suppression
(70.2%), abnormal liver aminotransferases levels (29.4%),
and renal dysfunction (20.3%). However, these adverse
events were generally well tolerated and most of these
events could be possibly pronounced by underlying dis-
eases, other medications, or concurrent organ dysfunc-
tion, without a direct causal relationship to daptomycin.
Overall, three patients discontinued daptomycin due to
these adverse events. CPK levels higher than ULN were
found in 16 of 61 patients (26.2%). After exclusion of
other causes, such as acute coronary syndrome or renal
failure, four patients (6.6%) had elevations of CPK level
related to use of daptomycin, with the peak CPK levels
ranging from 952 to 6528 IU/L. All the four patients
with elevations of CPK level had received higher than
8 mg/kg of daptomycin (range, 8.62- 11.11 mg/kg).
Three of these events occurred at ≥ 13 days of daptomycin
therapy (range, 4–21 days). Only one patient had symp-
toms of skeletal myopathy. Two of our 67 patients
received statins concurrently, but neither had elevations of
CPK level by definition. These events resolved after
discontinuation of daptomycin. No patients developed
eosinophilic pneumonia, which is a rare but well-
documented adverse reaction to daptomycin [27].
Discussion
This cohort study demonstrated that salvage therapy using
daptomycin at high doses (> 6 mg/kg to 12 mg/kg) for
prior antibiotic treatment failure and intolerance was gen-
erally effective and well-tolerated in Taiwanese patients.
For use of high-dose daptomycin, only two prospective
clinical studies had been published to date [11,15], and
all studies were done in western countries (Italy and
the United States). To our knowledge, this is the first
clinical data describing the use of daptomycin at more
than 6 mg/kg in Asian populations. Nearly 90% of our
patients received daptomycin following vancomycin or
teicoplanin failure, probably owing to the requirement
of prospective audit in NTUH. Pre-exposure of glyco-
peptide might result in elevated MIC of both vancomycin
and daptomycin simultaneously [5,24,28-30]. Our results
support using higher dose of daptomycin for difficult-to-
treat infections caused by resistant pathogens, compatible
with other reports [13-17].
The clinical success rates of treatment with high dose
daptomycin were 75-94% in the literature [13,15-17].
Bassetti et al. compared patients receiving daptomycin at
doses > 6 mg/kg/day and those receiving ≤ 6 mg/kg/day
(standard doses) in documented S. aureus infections [13].
Both microbiological success (93% versus 68%, p < 0.05)
and clinical success (94% versus 73%, P = 0.05) were sig-
nificantly superior in the high dose group than the stand-
ard dose group. However, the duration of therapy was also
significantly longer in the high dose group, which may be
a potential limitation. In our cohort, the clinical success
rate was 77.6% overall, 80.5% in ICU patients, 79.6% in
patients with bacteremia, or 79.2% in patients with MRSA
isolates with vancomycin MIC ≥ 2 μg/mL. Compared to
patients receiving ≤ 8 mg/kg of daptomycin, those treated
with daptomycin > 8 mg/kg did not have better clinical
outcomes but had higher rates of CPK level elevations.
The optimal dose of daptomycin is still unknown. In
this study, we failed to demonstrate better survival
rate, clinical success or microbiological success in pa-
tients with daptomycin > 8 mg/kg, compared with those
with ≤ 8 mg/kg. It is possible that the physicians in charge
tended to prescribe higher doses for sicker patients with
more severe infections. However, the baseline characteris-
tics (including Charlson index, Pitt score, ICU stay, and
SOFA score) were similar between these two dosing
groups, except that more patients with endocarditis were
treated with doses > 8 mg/kg. In addition, our small sam-
ple size may lack sufficient power to detect small differ-
ences between treatment groups. To determine the
efficacy of treatment with daptomycin > 8 mg/kg, further
investigations in larger cohorts with randomization are
warranted.
Approximately 60% of our patients received high-dose
daptomycin during ICU admission. This proportion of
ICU stay (61.2%) in our cohort is higher than prior reports
(25-36%) [17,31]. These ICU patients did not have worse
clinical responses or microbiologic outcome despite of
higher mortality rate. The efficacy of high-dose daptomy-
cin might be similar in critically-ill patients, and further
investigations are needed to confirm our finding.
Overall, defined CPK level elevations occurred in 6.6%
of patients in this study. This incidence was similar to
the findings from previous studies of high dose dapto-
mycin therapy (3.2-8.3%) [2,13-15,17]. In our study, the
incidence of defined CPK level elevations was significantly
higher in patients treated with daptomycin > 8 mg/kg
(16.7% versus 0%, p = 0.02). This finding is not unex-
pected, since Bhavnani et al. demonstrated that both
AUC and minimum serum concentration (Cmin) of dap-
tomycin were significantly associated with CPK eleva-
tions. A Cmin ≥ 24.3 mg/L could lead to a > 30-fold
higher risk of CPK elevations. By using Monte Carlo
simulations, they also established probabilities of elevated
CPK levels stratified by dose [26]. Among our patients
with daptomycin > 8 mg/kg, the rate of elevated CPK
levels (16.7%) was slightly higher than their prediction
(10.7-15.3%). These findings indicate the association of
musculoskeletal toxicity with higher doses of daptomycin.
Our results also confirmed that CPK level elevations
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became apparent about 2-week use of daptomycin [26].
Potential adverse events of musculoskeletal toxicity should
be alerted if prolonged use of high dose daptomycin, espe-
cially after 2 weeks of daptomycin therapy.
Figueroa et al. reported 61 patients treated with a mean
dose of 8 mg/kg of daptomycin for a median of 25 days,
and 3 patients had musculoskeletal symptoms with grade
3 CPK level elevations (>1000 U/L). All three patients
received 8 mg/kg of daptomycin and two of them had
body mass index (BMI) class III obesity [14]. In the study
from Bhavnani et al., 4 of 6 patients with elevated CPK
levels were obese [26]. According to the daptomycin pack-
age insert, total body weight (TBW) is the appropriate
dosing weight. But dosing daptomycin based on TBW can
result in significantly higher maximum serum concentra-
tion and AUC in morbidly obese subjects [32]. This could
explain why obesity was a risk factor for CPK elevation
[26]. However, among our 4 patients with elevations of
CPK level, none were obese (BMI range, 17.9-28.7 kg/m2;
median, 23.4 kg/m2). Clinicians should be aware of mus-
culoskeletal toxicity of high-dose daptomycin, even in
non-obese patients.
As an observational, uncontrolled, nonrandomized study
with a small sample size, there are limitations in our study.
First, our study was based on clinical observation, therefore
routine follow-up of cultures and CPK levels at regular
intervals were not mandatory. Second, we did not check
MIC of daptomycin, and only 77.4% of MRSA isolates were
checked for MIC of vancomycin. Third, we did not per-
form pharmacokinetic analyses.
Conclusion
Our study provided relevant clinical information on high
dose (> 6 mg/kg)daptomycin as salvage therapy for Asian
populations. High dose daptomycin was effective and
well tolerated. Patients treated with doses > 8 mg/kg had
a significant higher incidence of elevated CPK levels.
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